share_log

復星醫藥：關連交易有關增持目標基金份額

FOSUN PHARMA: CONNECTED TRANSACTIONS IN RELATION TO ACQUISITION OF EQUITY INTERESTS IN THE TARGET FUNDS

HKEX ·  Dec 11, 2024 07:50

Summary by Futu AI

復星醫藥附屬公司寧波復瀛擬以總額約1.4億元人民幣增持三家基金份額。具體包括以9092萬元受讓南京星健睿贏基金25.09%份額、2500萬元受讓大連星未來基金10%份額、2450萬元受讓蘇州星盛園豐基金25%份額。交易完成後，復星醫藥在三家基金的持股比例將分別增至66.24%、51%和64.2%。這三家基金主要投資於醫療健康領域的創新企業，涵蓋生物醫藥、醫療器械等方向。本次交易構成關連交易，因為賣方復星高科技為復星醫藥的控股股東。董事會認為交易條款公平合理，符合公司及股東整體利益。相關董事已迴避表決，獨立董事一致通過該決議。
復星醫藥附屬公司寧波復瀛擬以總額約1.4億元人民幣增持三家基金份額。具體包括以9092萬元受讓南京星健睿贏基金25.09%份額、2500萬元受讓大連星未來基金10%份額、2450萬元受讓蘇州星盛園豐基金25%份額。交易完成後，復星醫藥在三家基金的持股比例將分別增至66.24%、51%和64.2%。這三家基金主要投資於醫療健康領域的創新企業，涵蓋生物醫藥、醫療器械等方向。本次交易構成關連交易，因為賣方復星高科技為復星醫藥的控股股東。董事會認為交易條款公平合理，符合公司及股東整體利益。相關董事已迴避表決，獨立董事一致通過該決議。
FOSUN PHARMA's subsidiary, Ningbo Fuying, plans to increase its shareholding in three funds for a total amount of approximately 0.14 billion yuan. Specifically, it includes acquiring a 25.09% share in Nanjing Xingjianruiying Fund for 90.92 million yuan, a 10% share in Dalian Xingweilai Fund for 25 million yuan, and a 25% share in Suzhou Xingshengyuanfeng Fund for 24.5 million yuan.After the Trade is completed, FOSUN PHARMA's stake in the three funds will increase to 66.24%, 51%, and 64.2%, respectively. These three funds primarily invest in innovative companies in the healthcare sector, covering areas such as Biomedical and medical instruments.This transaction constitutes a related-party transaction, as the seller, FOSUN High Technology, is the controlling shareholder of FOSUN PHARMA. The Board of Directors believes that the transaction terms are fair and reasonable, in line with the overall interests of the Company and its Shareholders. Relevant directors have abstained from voting, and independent directors have unanimously approved the resolution.
FOSUN PHARMA's subsidiary, Ningbo Fuying, plans to increase its shareholding in three funds for a total amount of approximately 0.14 billion yuan. Specifically, it includes acquiring a 25.09% share in Nanjing Xingjianruiying Fund for 90.92 million yuan, a 10% share in Dalian Xingweilai Fund for 25 million yuan, and a 25% share in Suzhou Xingshengyuanfeng Fund for 24.5 million yuan.After the Trade is completed, FOSUN PHARMA's stake in the three funds will increase to 66.24%, 51%, and 64.2%, respectively. These three funds primarily invest in innovative companies in the healthcare sector, covering areas such as Biomedical and medical instruments.This transaction constitutes a related-party transaction, as the seller, FOSUN High Technology, is the controlling shareholder of FOSUN PHARMA. The Board of Directors believes that the transaction terms are fair and reasonable, in line with the overall interests of the Company and its Shareholders. Relevant directors have abstained from voting, and independent directors have unanimously approved the resolution.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated